Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP59499.RA8NmTpLLZCBpwA3P_79x7FrR2-q6bREx2dTPQDLAf_RE130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP59499.RA8NmTpLLZCBpwA3P_79x7FrR2-q6bREx2dTPQDLAf_RE130_assertion type Assertion NP59499.RA8NmTpLLZCBpwA3P_79x7FrR2-q6bREx2dTPQDLAf_RE130_head.
- NP59499.RA8NmTpLLZCBpwA3P_79x7FrR2-q6bREx2dTPQDLAf_RE130_assertion description "[XRCC3 241 MetMet is an independent determinant of favorable survival in NSCLC patients treated with cisplatin/gemcitabine.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP59499.RA8NmTpLLZCBpwA3P_79x7FrR2-q6bREx2dTPQDLAf_RE130_provenance.
- NP59499.RA8NmTpLLZCBpwA3P_79x7FrR2-q6bREx2dTPQDLAf_RE130_assertion evidence source_evidence_literature NP59499.RA8NmTpLLZCBpwA3P_79x7FrR2-q6bREx2dTPQDLAf_RE130_provenance.
- NP59499.RA8NmTpLLZCBpwA3P_79x7FrR2-q6bREx2dTPQDLAf_RE130_assertion SIO_000772 16407418 NP59499.RA8NmTpLLZCBpwA3P_79x7FrR2-q6bREx2dTPQDLAf_RE130_provenance.
- NP59499.RA8NmTpLLZCBpwA3P_79x7FrR2-q6bREx2dTPQDLAf_RE130_assertion wasDerivedFrom gad-20130706 NP59499.RA8NmTpLLZCBpwA3P_79x7FrR2-q6bREx2dTPQDLAf_RE130_provenance.
- NP59499.RA8NmTpLLZCBpwA3P_79x7FrR2-q6bREx2dTPQDLAf_RE130_assertion wasGeneratedBy ECO_0000203 NP59499.RA8NmTpLLZCBpwA3P_79x7FrR2-q6bREx2dTPQDLAf_RE130_provenance.